Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Europe Finance Weekly.
Press releases published on May 7, 2025

Elcogen and Casale SA collaborate to drive innovation in green ammonia and sustainable energy
Tallinn, ESTONIA, May 07, 2025 (GLOBE NEWSWIRE) -- Elcogen, a leading European manufacturer of technology that enables the efficient production of affordable green hydrogen and emission-free electricity, today announced that it h entered into a Memorandum …

Vishay Intertechnology Reports First Quarter 2025 Results
MALVERN, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vishay Intertechnology, Inc., (NYSE: VSH), one of the world's largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal first quarter ended …

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination …

Verisk Reports First-Quarter 2025 Financial Results
First quarter revenue of $753 million, up 7.0%, and up 7.9% on an organic constant currency (OCC) basis. Net income of $232 million, up 5.9%. Adjusted EBITDA, a non-GAAP measure, of $417 million, up 9.5%, and up 9.5% on an OCC basis. Diluted GAAP earnings …

Vertex Announces First Quarter 2025 Financial Results
KING OF PRUSSIA, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its first quarter ended March 31, 2025. “Vertex …

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …

Avista Corp. Reports Financial Results for the First Quarter of 2025, Confirms 2025 Earnings Guidance
SPOKANE, Wash., May 07, 2025 (GLOBE NEWSWIRE) -- Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2025. Net income and earnings per diluted share for the first quarter of 2025 compared to the first quarter of 2024 are …

TransAlta Reports First Quarter 2025 Results and Reaffirms Annual Guidance
CALGARY, Alberta, May 07, 2025 (GLOBE NEWSWIRE) -- TransAlta Corporation (TransAlta or the Company) (TSX: TA) (NYSE: TAC) today reported its financial results for the first quarter ended March 31, 2025. "Our business delivered strong operational …

Hain Celestial Reports Fiscal Third Quarter 2025 Financial Results
HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its …

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …

Sprott Announces First Quarter 2025 Results
TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the quarter ended March 31, 2025. Management commentary "Sprott’s Assets Under Management (“AUM”) ended the first …

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …

Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On …

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …

Climb Channel Solutions Partners with Smartsheet for Industry-Leading Collaborative Work Management
EATONTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is excited to be adding Smartsheet, the AI-enhanced …

Dayforce Reports First Quarter 2025 Results¹
Dayforce® recurring revenue, excluding float, of $323 million, up 14%, or 16% on a constant currency basis Total revenue of $482 million, up 12%, and excluding float, up 15%, or 17% on a constant currency basis Net cash provided by operating activities of …

Chicago Atlantic Real Estate Finance Announces First Quarter 2025 Financial Results
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the first quarter ended March 31, …

Amarin Reports First Quarter 2025 Financial Results
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing …

KVH Industries Reports First Quarter 2025 Results
MIDDLETOWN, R.I., May 07, 2025 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended March 31, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can …

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease …